Giles Platford/LinkedIn
Dec 12, 2025, 09:34
Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, shared on LinkedIn:
”Plasma-derived therapies are often the only effective treatment for patients with certain rare and complex, chronic conditions.
One case in point is infant botulism: in partnership with the California Department of Public Health, on a non-profit basis, Takeda produces the only FDA-approved treatment for this condition, Baby Big.
The recent outbreak of infant botulism in the U.S. has put a fine point on the importance of this therapy.
Learn more in this story from The Independent”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation